Relapse and therapy resistance remain major barriers to improving clinical outcomes in acute myeloid leukemia (AML), underscoring the need for actionable therapeutic targets. In this study, we identify calcium/calmodulin-dependent protein kinase II delta (CaMK... ...

请注册登录后继续浏览